Q3 2025 EPS Estimates for Kodiak Sciences Inc. Reduced by Zacks Research (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD) – Research analysts at Zacks Research lowered their Q3 2025 EPS estimates for Kodiak Sciences in a report released on Tuesday, August 13th. Zacks Research analyst R. Department now expects that the company will earn ($0.79) per share for the quarter, down from their prior forecast of ($0.78). The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.55) per share. Zacks Research also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.34) EPS, Q1 2026 earnings at ($0.47) EPS and Q2 2026 earnings at ($0.38) EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.27.

Kodiak Sciences Price Performance

Shares of NASDAQ KOD opened at $2.47 on Thursday. Kodiak Sciences has a 1-year low of $1.37 and a 1-year high of $7.77. The business’s 50 day moving average is $2.68 and its two-hundred day moving average is $3.87. The stock has a market capitalization of $129.76 million, a P/E ratio of -0.56 and a beta of 2.38.

Hedge Funds Weigh In On Kodiak Sciences

Several large investors have recently modified their holdings of KOD. American Century Companies Inc. raised its position in Kodiak Sciences by 18.5% in the 2nd quarter. American Century Companies Inc. now owns 54,323 shares of the company’s stock worth $128,000 after purchasing an additional 8,470 shares during the period. Headlands Technologies LLC bought a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $50,000. Vanguard Group Inc. lifted its stake in shares of Kodiak Sciences by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock worth $8,702,000 after acquiring an additional 10,978 shares during the last quarter. Nan Fung Group Holdings Ltd boosted its holdings in Kodiak Sciences by 62.7% during the 1st quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company’s stock valued at $168,000 after acquiring an additional 12,300 shares during the period. Finally, Oxford Asset Management LLP bought a new position in Kodiak Sciences in the 4th quarter valued at $41,000. Institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.